AstraZeneca’s chief executive has insisted the UK will come first for vaccines as he rejected calls to divert doses to the European Union following a breakdown in supply.
Amid a growing row, Pascal Soriot, the French head of the pharmaceutical giant, said the UK was benefiting from being early to sign a contract for 100m doses.
There is growing anger in Brussels and EU capitals at AstraZeneca’s announcement on Friday of a shortfall of more than 60% on the intended schedule of deliveries to the bloc in the first quarter of this year.
While the UK has administered vaccine first doses to about 10% of adults and plans to vaccinate the most vulnerable 15 million – including all over-70s – by mid-February, the EU has reached 2% so far. The UK’s regulator approved the Oxford/AstraZeneca vaccine in late December and the EU’s is expected to do so on Friday.
But Soriot said Downing Street would have first claim on the doses manufactured in the UK and that the EU would have to wait. “The UK agreement was reached in June, three months before the European one,” he said. “As you could imagine, the UK government said the supply coming out of the UK supply chain would go for the UK first. Basically, that’s how it is.”
The European commission did not deny claims on Tuesday that during heated talks EU officials had asked the Anglo-Swedish company to redirect doses made in the UK to make up for problems at a Belgian plant.
In a speech to the World Economic Forum on Tuesday, the president of the European commission, Ursula von der Leyen, made clear her anger at AstraZeneca’s approach, warning the EU “means business”.
“The EU and others helped with money to build research capacities and production facilities,” she said. “Europe invested billions to help develop the world’s first Covid-19 vaccines. To create a truly global common good. And now, the companies must deliver. They must honour their obligations.”
The commission is to release details of a new export register by the end of the week to oblige vaccine suppliers to notify it of exports – with the German government raising the spectre of a block on the movement of doses outside the EU.
Soriot called for calm, insisting the UK had a right to the doses produced with scientists at Oxford University. In an interview with the Italian newspaper La Repubblica, he said: “In the EU agreement it is mentioned that the manufacturing sites in the UK were an option for Europe – but only later. But we’re moving very quickly, the supply in the UK is very rapid.
https://www.theguardian.com/world/2021/ ... on-vaccine